Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Chugai Picks Galderma as Global Partner for Antibody Atopic Dermatitis Drug
Chugai Pharmaceutical has inked a global licensing pact with Swiss-based Galderma Pharma S.A. for its hope-to-be blockbuster nemolizumab, an antibody being developed for the treatment of atopic dermatitis and pruritus in hemodialysis patients, the two companies said on July 21.…
To read the full story
Related Article
- Chugai-Originated Eczema Drug Hits Primary Goal in Japan PIII: Maruho
April 19, 2019
- Galderma Delivers in PIIb Atopic Dermatitis Study for Nemolizumab, Originated by Chugai
March 12, 2019
- Japan PIII for Atopic Dermatitis Drug Nemolizumab to Begin in October: Maruho
September 8, 2017
- Chugai Licenses Atopic Dermatitis Hopeful to Maruho in Japan, Retains Rights for Hemodialysis Pruritus
September 29, 2016
- Chugai Scores Solid Half-Year Sales on Meds for Cancer, Bone and Joint Disease
July 22, 2016
- Sanofi’s Antibody Drug for Atopic Dermatitis Close to Regulatory Filing
June 23, 2016
BUSINESS
- FDA Resumes Review of Capricor/Nippon Shinyaku’s DMD Cell Therapy
March 12, 2026
- Hisamitsu Starts Promotion of Yaz AGs under Bayer Alliance
March 11, 2026
- Seagen ADC Patent Dispute Ends with Daiichi Sankyo Victory
March 11, 2026
- Seikagaku Re-Files Herniated Disk Drug with US FDA
March 11, 2026
- Lotte to Step Up CVC Investments to Drive CDMO Synergies
March 10, 2026
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…